Elsevier

Pharmacology & Therapeutics

Volume 155, November 2015, Pages 49-59
Pharmacology & Therapeutics

Rare sugar d-allulose: Potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus

https://doi.org/10.1016/j.pharmthera.2015.08.004Get rights and content

Abstract

Obesity and type 2 diabetes mellitus (T2DM) are the leading worldwide risk factors for mortality. The inextricably interlinked pathological progression from excessive weight gain, obesity, and hyperglycemia to T2DM, usually commencing from obesity, typically originates from overconsumption of sugar and high-fat diets. Although most patients require medications, T2DM is manageable or even preventable with consumption of low-calorie diet and maintaining body weight. Medicines like insulin, metformin, and thiazolidinediones that improve glycemic control; however, these are associated with weight gain, high blood pressure, and dyslipidemia. These situations warrant the attentive consideration of the role of balanced foods. Recently, we have discovered advantages of a rare sugar, d-allulose, a zero-calorie functional sweetener having strong anti-hyperlipidemic and anti-hyperglycemic effects. Study revealed that after oral administration in rats d-allulose readily entered the blood stream and was eliminated into urine within 24 h. Cell culture study showed that d-allulose enters into and leaves the intestinal enterocytes via glucose transporters GLUT5 and GLUT2, respectively. In addition to d-allulose's short-term effects, the characterization of long-term effects has been focused on preventing commencement and progression of T2DM in diabetic rats. Human trials showed that d-allulose attenuates postprandial glucose levels in healthy subjects and in borderline diabetic subjects. The anti-hyperlipidemic effect of d-allulose, combined with its anti-inflammatory actions on adipocytes, is beneficial for the prevention of both obesity and atherosclerosis and is accompanied by improvements in insulin resistance and impaired glucose tolerance. Therefore, this review presents brief discussions focusing on physiological functions and potential benefits of d-allulose on obesity and T2DM.

Introduction

Currently, the incidence and prevalence of excessive weight gain followed by obesity has dramatically increased throughout the world, with the consequence that an estimated 325 million diabetes sufferers will exist during the next 25 years (Wild et al., 2004). Over consumption of sugar and high-fat diets are considered the main causative dietary factors of this situation (Giugliano & Esposito, 2008). Beyond the availability of a number of pharmacological and surgical treatments, lifestyle modifications (Asif, 2014) involving the consumption of foods with low energy density in addition to increasing physical activities are the basic therapeutic strategies to prevent the development of type 2 diabetes mellitus (T2DM).

Recently, we have been studying rare sugars that are defined as “monosaccharides and their derivatives that are rare in nature” by the International Society of Rare Sugars (https://sites.google.com/site/raresugars/). There are more than 50 kinds of rare sugar. One of them, d-allulose (previously named d-psicose), has been determined to have a low degree of energy density, exhibiting almost zero calories (Matsuo et al., 2002a) and thus has been proven to be a unique metabolic regulator of glucose and fat metabolism in a number of basic research (Hossain et al., 2011, Hossain et al., 2012, Matsuo and Izumori, 2006, Matsuo and Izumori, 2009) and clinical (Iida et al., 2013) studies. d-Allulose has demonstrated activity involving a variety of mechanisms, such as strong anti-oxidative effects, inhibitory activity toward intestinal digestive enzymes, enhanced translocation of glucokinase (GK) from the hepatic nucleus to cytoplasm, and competitive transport with glucose through the intestinal mucosa. Therefore, this review will summarize the physical properties, absorption, excretion, and physiological functions of d-allulose, as well as the potential benefits of d-allulose on obesity and T2DM with its safety and possible use as a substitute for conventional sugars.

d-Allulose is a monosaccharide with a molecular formula C6H12O6. It is a C-3 epimer of d-fructose (Fig. 1), and its systematic name is d-ribo-2-hexulose. d-Allulose is also called d-psicose and the name “psicose” is derived from the antibiotic psicofuranine, from which it was isolated (Eble et al., 1959). d-Allulose is rarely encountered in nature as a component of some plants, such as Itea plants (Zuina) (Poonperm et al., 2007), and certain bacteria (Zhang et al., 2009), but not in higher animals. d-Allulose contains one ketone group and acts as a reducing agent. It is prepared as a white, odorless powder and is easily dissolved in water. The sweetness of d-allulose is about 70% of sucrose, melts at 90 °C, and forms caramel. As a reducing sugar, heating with amino acids, peptides, and proteins in foods induces the amino-carbonyl reaction (Maillard reaction) at a lower degree than d-glucose or d-fructose (Sun et al., 2004). These Maillard products show anti-oxidative activity and gelling properties, such as enhanced gel strength and water-holding capacity (Sun et al., 2006).

Although it is rarely found in nature, it has been reported that commercial mixtures of d-glucose and d-fructose obtained from the hydrolysis of sucrose or d-glucose isomerization (Cree & Perlin, 1968), as well as processed cane and beet molasses (Binkley and Wolfrom, 1953, Thacker and Toyoda, 2009), contain a small quantity of d-allulose as a result of the heating process during manufacturing. After the discovery of the key enzyme d-tagatose 3-epimerase, which converts d-fructose to d-allulose, mass production began (Izumori, 2006, Takeshita et al., 2000). Currently, d-allulose is also produced by chemical synthesis and is widely available at a much lower cost. Thus, various d-allulose-added foods have been prepared and marketed in Japan. d-Allulose was approved as generally recognized as safe (GRAS) by the US Food and Drug Administration (FDA) in June 2014 (GRAS Notice No. GRN 498) and is allowed to be used as an ingredient in a variety of foods and dietary supplements (Mu et al., 2012).

In addition to its use as a substitute sweetener, d-allulose was also reported to inhibit trichomonad growth by reinforcing the action of metronidazole (Harada et al., 2012), and to induce the up-regulation of defense-related genes in plant cultivation (Kano et al., 2011). Further research into its use as an anti-parasitic or herbicide is currently being undertaken.

Section snippets

Absorption, metabolism, and organ distribution of d-allulose

14C-Labelled d-allulose was enzymatically synthesized (Morimoto et al., 2006) to study its absorption, distribution, and elimination after both intravenous and oral administration in Wister rats and the concentrations in whole blood, urine, and organs were measured. d-Allulose (100 mg/kg) was orally administered to rats that were subsequently sacrificed 10, 30, 60, and 120 min after administration. The concentrations of d-allulose in urine were 19% and 37% of the administered dose at 60 and 120 

Effect of d-allulose on sugar absorption through rat intestinal mucosa

Sugar absorption occurs primarily in the small intestine. It has been shown that d-allulose is also absorbed from the small intestine and released into the bloodstream (Iida et al., 2010, Tsukamoto et al., 2014). Monosaccharide uptake into enterocytes of the human intestinal lumen is mediated by a sugar transporter located on the apical membrane (brush border membrane), while efflux from enterocytes to the lamina propria is mediated by a different sugar transporter located in the basolateral

Translocation of d-allulose-induces hepatic glucokinase to enhance hepatic glucose utilization

Hepatic d-glucose metabolism is regulated via the shuttling of glucokinase (GK) between the nucleus and cytoplasm (Fig. 3). Glucokinase (ATP:d-hexose 6-phosphotransferase, EC 2.7.1.1) catalyzes the phosphorylation of d-glucose to glucose-6-phosphate, which is the rate-limiting step in glycolysis, and maintains glucose homeostasis (Matschinsky, 2009). This enzyme is expressed mainly in pancreatic β cells and hepatocytes and is also present in certain hypothalamic neurons and enteroendocrine

Anti-hyperglycemic effects of d-allulose in normal rats

The anti-hyperglycemic effects of d-allulose are summarized as a schematic in Fig. 4. It has been proven that strict glycemic control is associated with a low incidence of both micro- and macro-vascular complications in diabetes, and a delay or inhibition of carbohydrate digestion could be helpful in avoiding postprandial hyperglycemia (Toeller, 1992). Specific inhibitors of α-glucosidase have exhibited a definite therapeutic value in suppressing the postprandial glycemic increase by delaying

Anti-hyperglycemic and anti-inflammatory effects of d-allulose in diabetic rats

T2DM is a syndrome characterized by high blood glucose in the context of defective insulin secretion and insulin resistance (Aizawa et al., 1995, Gerich, 1998), precipitating the following adverse consequences: deregulated glucose transport into cells (Choi et al., 2007), decreased glucose utilization by the liver and peripheral tissues, and increased glucose production by the liver (Mevorach et al., 1998). Together, these changes result in the development of insulin resistance. Through several

Anti-hyperlipidemic effects of d-allulose

Uncontrolled intake of sugar-sweetened beverages, like sucrose or corn syrup (both include d-fructose), has been the focus of investigation as one of the causes of obesity (Malik et al., 2006, Schulze et al., 2004). Because d-fructose is known to be lipogenic and related to the development of metabolic syndrome (Rutledge & Adeli, 2007), d-allulose, an epimer of d-fructose, may also be lipogenic. However, as mentioned below, d-allulose has anti-hyperlipidemic and anti-obesity potential. We have

Clinical trials of d-allulose on normal and borderline diabetic people

The rapidly increasing incidence of obesity, obesity-induced T2DM, and the cost of managing the chronic complications of these disorders are becoming an enormous problem in the modern world. Therefore, it is of prime importance to look for effective therapeutic interventions for both the prevention and treatment of diabetes and its complications (Takeuchi et al., 1996). The rare sugar d-allulose has attracted much attention for its promising anti-hyperglycemic and anti-hyperlipidemic effects in

Conclusion

d-Allulose is a rare sugar with almost zero calories, sweetness that is 70% of sucrose, with some cooling sensation and no bitterness. Trace amounts of d-allulose are found naturally in the leaves of Itea, a plant found in Southeast Asia, including Japan. Presently, a large amount of d-allulose is being produced through enzymatic methods discovered by a research group at Kagawa University, Japan. In this review, we focused mainly the physiological functions of d-allulose with a view to

Conflicts of interest

The authors declare that there are no conflicts of interest.

References (107)

  • A. Kano et al.

    d-Psicose induces upregulation of defense-related genes and resistance in rice against bacterial blight

    J Plant Physiol

    (2011)
  • V.S. Malik et al.

    Intake of sugar-sweetened beverages and weight gain: A systematic review

    Am J Clin Nutr

    (2006)
  • K. Morimoto et al.

    Large scale production of d-allose from d-psicose using continuous bioreactor and separation system

    Enzyme Microb Technol

    (2006)
  • K. Murao et al.

    d-Psicose inhibits the expression of MCP-1 induced by high-glucose stimulation in HUVECs

    Life Sci

    (2007)
  • T. Nakamura et al.

    Anti-oxidative effects of d-allose, a rare sugar, on ischemia-reperfusion damage following focal cerebral ischemia in rat

    Neurosci Lett

    (2011)
  • W. Poonperm et al.

    Efficient conversion of allitol to d-psicose by Bacillus pallidus Y25

    J Biosci Bioeng

    (2007)
  • C. Postic et al.

    Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase

    J Biol Chem

    (1999)
  • W. Puls et al.

    Inhibition of sucrase by tris in rat and man, demonstrated by oral loading tests with sucrose

    Metabolism

    (1975)
  • T.J. Schall et al.

    Chemokines, leukocyte trafficking, and inflammation

    Curr Opin Immunol

    (1994)
  • S.E. Swithers

    Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements

    Trends Endocrinol Metab

    (2013)
  • M.K. Takata et al.

    Neuroprotective effect of d-psicose on 6-hydroxydopamine-induced apoptosis in rat pheochromocytoma (PC12) cells

    J Biosci Bioeng

    (2005)
  • K. Takeshita et al.

    Mass production of d-psicose from d-fructose by a continuous bioreactor system using immobilized d-tagatose 3-epimerase

    J Biosci Bioeng

    (2000)
  • H. Takeuchi et al.

    Overexpression of either liver type or pancreatic beta cell type glucokinase via recombinant adenovirus enhances glucose oxidation in isolated rat hepatocytes

    FEBS Lett

    (1996)
  • Y. Toyoda et al.

    Evidence for glucokinase translocation by glucose in rat hepatocytes

    Biochem Biophys Res Commun

    (1994)
  • T. Aizawa et al.

    Prophylaxis of genetically determined diabetes by diazoxide: A study in a rat model of naturally occurring obese diabetes

    J Pharmacol Exp Ther

    (1995)
  • M. Asif

    The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern

    J Educ Health Promot

    (2014)
  • S.H. Baek et al.

    d-Psicose, a sweet monosaccharide, ameliorate hyperglycemia, and dyslipidemia in C57BL/6J db/db mice

    J Food Sci

    (2010)
  • A. Basu et al.

    Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: Additional evidence for a defect in hepatic glucokinase activity

    Diabetes

    (2001)
  • A. Basu et al.

    Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: Evidence for a defect in hepatic glucokinase activity

    Diabetes

    (2000)
  • H. Bohets et al.

    Strategies for absorption screening in drug discovery and development

    Curr Top Med Chem

    (2001)
  • O. Bosello et al.

    Visceral obesity and metabolic syndrome

    Obes Rev

    (2000)
  • J.F. Caro et al.

    Liver glucokinase: Decreased activity in patients with type II diabetes

    Horm Metab Res

    (1995)
  • W.F. Caspary et al.

    Inhibition of human intestinal alpha-glucosidehydrolases by a new complex oligosaccharide

    Res Exp Med (Berl)

    (1979)
  • A.D. Cherrington

    Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo

    Diabetes

    (1999)
  • S.H. Choi et al.

    The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats

    Diabetes Metab Res Rev

    (2007)
  • Y.M. Chung et al.

    Dietary d-psicose reduced visceral fat mass in high-fat diet-induced obese rats

    J Food Sci

    (2012)
  • K.C. Coate et al.

    Portal vein glucose entry triggers a coordinated cellular response that potentiates hepatic glucose uptake and storage in normal but not high-fat/high-fructose-fed dogs

    Diabetes

    (2013)
  • G.M. Cree et al.

    O-isopropylidene derivatives of d-allulose (d-psicose) and d-erythro-hexopyranos-2,3-diulose

    Can J Biochem

    (1968)
  • V. Douard et al.

    Regulation of the fructose transporter GLUT5 in health and disease

    Am J Physiol Endocrinol Metab

    (2008)
  • T.E. Eble et al.

    Psicofuranine. I. Discovery, isolation, and properties

    Antibiot Chemother (Northfield III)

    (1959)
  • S. Efrat et al.

    Ribozyme-mediated attenuation of pancreatic beta-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion

    Proc Natl Acad Sci U S A

    (1994)
  • Y. Fujimoto et al.

    Defect in glucokinase translocation in Zucker diabetic fatty rats

    Am J Physiol Endocrinol Metab

    (2004)
  • J.E. Gerich

    The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity

    Endocr Rev

    (1998)
  • D. Giugliano et al.

    Mediterranean diet and metabolic diseases

    Curr Opin Lipidol

    (2008)
  • M.F. Gregor et al.

    Inflammatory mechanisms in obesity

    Annu Rev Immunol

    (2011)
  • M. Harada et al.

    d-Allose and d-psicose reinforce the action of metronidazole on trichomonad

    Parasitol Res

    (2012)
  • N. Hayashi et al.

    Study on the postprandial blood glucose suppression effect of d-psicose in borderline diabetes and the safety of long-term ingestion by normal human subjects

    Biosci Biotechnol Biochem

    (2010)
  • A.W. Herling et al.

    Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system

    Am J Physiol

    (1998)
  • T. Hishiike et al.

    Transepithelial transports of rare sugar d-psicose in human intestine

    J Agric Food Chem

    (2013)
  • D.L. Horwitz et al.

    Response to single dose of aspartame or saccharin by NIDDM patients

    Diabetes Care

    (1988)
  • Cited by (146)

    View all citing articles on Scopus
    View full text